Portal de Periódicos da CAPES

Bilateral acute anterior uveitis after alendronate

2002; BMJ; Volume: 86; Issue: 12 Linguagem: Inglês

10.1136/bjo.86.12.1443

1468-2079

Ammar Malik,

Bone and Joint Diseases

Biphosphonates are increasingly being used for the prevention and treatment of osteoporosis in women where hormone replacement therapy is contraindicated.1,2 Alendronate (Fosamax) is a potent aminobiphosphonate that reduces bone resorption and increases bone mass and therefore reduces the incidence of fractures in postmenopausal women with osteoporosis.2 The most common adverse effects are upper gastrointestinal, including dysphagia, heartburn, oesophagitis, and oesophageal strictures. We report a case of bilateral acute anterior uveitis following the use of alendronate (once weekly 70 mg tablet). This is the first reported case of bilateral acute anterior uveitis associated with alendronate. A 57 year old woman had been taking oral alendronate 10 mg daily for a year without experiencing any eye problems. To simplify the regimen her general practitioner proposed a single weekly dose …